small molecule

FERABRIGHT

FERUMOXYTOL

Loss of exclusivityOctober 2028FDA regulatory exclusivity expiry
CompanyAZURITY PHARMACEUTICALS SWITZERLAND GMBH

Drug detail

Brand nameFERABRIGHT
Active ingredientFERUMOXYTOL
StrengthEQ 300MG IRON/10ML (EQ 30MG IRON/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2025
Marketing statusRX

Regulatory exclusivity

CodeExpires
NPOctober 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

FERABRIGHT patent cliff — loss of exclusivity October 2028 | CliffBio